Sunday, March 29, 2026 – (MedPage Today) -- For patients with obesity and atrial fibrillation (Afib), GLP-1 receptor agonist drugs may be the weight loss approach that better addresses their arrhythmia, observational data suggested.
People who came out of catheter ablation...
Sunday, March 29, 2026 – The GLP-1 fight has moved from injectables to pills, and Structure Therapeutics Inc. is in the ring with phase III-ready aleniglipron. According to the Bay Area biotech, its oral once-daily glucagon-like peptide-1 (GLP-1) drug candidate, aleniglipron, demonstrated an absolute weight loss of “up to 39 pounds” in the 44-week Access II trial.
Sunday, March 29, 2026 – Weight loss drugs have been linked to an increased risk of premature births among women who took them inadvertently just before or during early pregnancy to treat pre-existing diabetes. However, a large study of over 750,000 pregnancies found that there was no link to preterm births or other obstetric complications if the medication was being used to lose weight. The authors of the study, published in Human Reproduction Open, say their findings suggest that it is diabetes rather than the drugs that may be contributing to the increased risk of preterm births.
Sunday, March 29, 2026 – Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults now take these medications, which also provide cardiovascular benefits. However, when patients stop taking these drugs, they not only regain weight, but, according to a new study, they also incur increased risk of heart attack, stroke, and death compared to staying on the medication.
Sunday, March 29, 2026 – The study findings may spark treatment innovations for depression and anxiety.
Sunday, March 29, 2026 – GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, a new study shows. The large register-based study was carried out in collaboration between the University of Eastern Finland, Karolinska Institutet in Stockholm and Griffith University in Australia.
Sunday, March 29, 2026 – In a sea of uncertainty, a large-scale, long-term Swedish study is the first to show that people using GLP-1 receptor agonists are less likely to have worsening mental illness. The study involved a national cohort of 95,490 people diagnosed with depression or anxiety disorder, who also were treated with any diabetes drug (apart from insulin).
Sunday, March 29, 2026 – INDIANAPOLIS, March 19, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational...
Sunday, March 29, 2026 – (MedPage Today) -- The FDA approved a higher dose of the GLP-1 receptor agonist semaglutide for weight loss, dubbed Wegovy HD, the agency announced on Thursday.
The once-weekly injectable will come in a 7.2-mg dose -- three times the strength...
Sunday, March 29, 2026 – A stronger version of the popular weight loss drug Wegovy is on the way after federal regulators signed off on a higher dose. The U.S. Food and Drug Administration (FDA) approved a 7.2-milligram dose of Novo Nordisk's semaglutide, the active ingredient in Wegovy. Until now, the highest approved dose was 2.4 milligrams, taken as a weekly shot.